Cytidinyl/Cationic Lipid Encapsulating Insulin-Like Growth Factor 1 Receptor siRNA for Hepatocellular Carcinoma Therapy
Molecular Pharmaceutics · 2025
DOI: 10.1021/acs.molpharmaceut.4c01318 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Yang Pu und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Receptor, IGF Type 1, RNA, Small Interfering, Liver Neoplasms. Die Arbeit nennt 51 Literaturangaben. Gefördert von: Natural Science Foundation of Beijing Municipality, Beijing Daxing Biomedical Industry Base.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is the most prevalent form of invasive liver cancer, representing over 90% of all liver cancer cases. Currently, there is a lack of targeted therapy for HCC. Insulin-like growth factor 1 receptor (IGF1R) is abnormally expressed in HCC, leading to the malignant proliferation and contributing to the antiapoptosis mechanisms in tumor cells. In this study, small interfering RNAs targeting IGF1R mRNA (siIGF1Rs) have been designed. Additionally, a full 2'-F/2'-OMe modification with partial phosphorothioation was applied to improve the biological properties of these siIGF1Rs. Based on previous research, stable lipid complexes with uniform particle sizes were constructed using cytidinyl lipid DNCA/cationic lipid CLD (Mix) supplemented with DSPE-PEG (siIGF1R/Mix/PEG). The complexes were formed through hydrogen-bonding, π-π stacking, and electrostatic interactions. The siIGF1R/Mix/PEG complex entered the cytoplasm and nucleus of HCC cells, reduced IGF1R mRNA and pre-mRNA levels by over 95% and 50% respectively, further arrested the cell cycle in the S phase, and promoted cell apoptosis. Importantly, siIGF1R/Mix/PEG (0.8 mg/kg, i.v.) selectively accumulated in the tumor, significantly inhibiting tumor growth by 91.31% compared to the naked siRNA group, with slower release and a more prolonged effect.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
- School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
- Genable (Beijing) Biotechnology Co. Ltd, #38 Yongda Road, Beijing 102609, China.
ORCID-Profile: Yufei Pan, Zhenjun Yang
Förderung
- Natural Science Foundation of Beijing Municipality
- Beijing Daxing Biomedical Industry Base
Zitieren
APA
Pu, Y., Wang, Q., Pan, Y., Wang, X., Guan, Z., Zhu, Y., & Yang, Z. (2025). Cytidinyl/Cationic Lipid Encapsulating Insulin-Like Growth Factor 1 Receptor siRNA for Hepatocellular Carcinoma Therapy. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c01318
Vancouver
Pu Y, Wang Q, Pan Y, Wang X, Guan Z, Zhu Y, et al. Cytidinyl/Cationic Lipid Encapsulating Insulin-Like Growth Factor 1 Receptor siRNA for Hepatocellular Carcinoma Therapy. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.4c01318
BibTeX
@article{Pu2025,
author = {Pu, Yang and Wang, Quanxin and Pan, Yufei and Wang, Xixian and Guan, Zhu and Zhu, Yuejie and Yang, Zhenjun},
title = {Cytidinyl/Cationic Lipid Encapsulating Insulin-Like Growth Factor 1 Receptor siRNA for Hepatocellular Carcinoma Therapy},
journal = {Molecular Pharmaceutics},
year = {2025},
doi = {10.1021/acs.molpharmaceut.4c01318}
}
EUVIMED